item management s discussion and analysis of financial condition and results of operations overview statements made in this form k  other than those concerning historical information  should be considered forward looking and subject to various risks and uncertainties 
such forward looking statements are made based on management s belief as well as assumptions made by  and information currently available to  management pursuant to the safe harbor provisions of the private securities litigation reform act of the company s actual results may differ materially from the results anticipated in these forward looking statements as a result of a variety of factors  including those identified in business and elsewhere in this annual report on form k for the fiscal year ended june  since its inception  the company has been engaged primarily in the research and development and  more recently  the commercialization of proprietary products relating to the detection  diagnosis and treatment of cancer and infectious diseases 
on june   the us food and drug administration fda licensed cea scan for use with other standard diagnostic modalities for the detection of recurrent and or metastatic colorectal cancer 
on october   the european commission granted marketing authorization for use of the product in the countries comprising the european union for the same indication 
on september   the company received a notice of compliance from the health protection branch permitting it to market cea scan in canada for colorectal cancer for recurrent and metastatic colorectal cancer 
on february   the company was granted regulatory approval by the european commission to market leukoscan  an in vivo infectious disease diagnostic imaging product  in all countries which are members of the european union  for the detection and diagnosis of osteomyelitis bone infection in long bones and in diabetic foot ulcer patients 
on december   the company filed a biologics license application for leukoscan with the fda for the same indication approved in europe  plus an additional indication for the diagnosis of acute  atypical appendicitis 
as with all filings  there can be no assurance that regulatory approval for such indications will be received 
the company is also engaged in developing other biopharmaceutical products  which are in various stages of development and clinical testing 
the company has not achieved profitable operations and does not anticipate achieving profitable operations during fiscal year the company will continue to experience operating losses until such time  if at all  that it is able to generate sufficient revenues from sales of cea scan  leukoscan and its other proposed in vivo products 
further  the company s working capital will continue to decrease until such time  if at all  that the company is able to generate positive cash flow from operations or until such time  if at all  that the company receives an additional infusion of cash from the sale of the company s securities  from other financing or from corporate alliances to finance the company s operating expenses and capital expenditures 
results of operations fiscal year compared to fiscal year revenues for fiscal year were  as compared to  in fiscal year  representing an increase of  the product sales for fiscal year were  as compared to  in fiscal year  representing an increase of  the increase in product sales is attributable to increased market acceptance of cea scan and the launch of leukoscan in april royalties and license fees for fiscal year decreased by  primarily due to the receipt of a nonrecurring  license fee from a corporate partner in fiscal research and development revenue for fiscal year increased by  as compared to fiscal  due to the recognition of previously deferred revenue received from pharmacia 
interest and other income for fiscal year increased by  primarily due to the receipt of an arbitration award of million  including interest  in its dispute with pharmacia offset by a decrease in interest income of  due to reduced levels of cash available for investments see liquidity and capital resources 
total operating expenses for fiscal year were  as compared to  in fiscal year  representing an increase of  research and development costs decreased by  as compared to the same period in  primarily due to a decrease in the level of expenditures required to obtain validation of the company s manufacturing facility and lower cost associated with reduced patient enrollment for clinical trials 
sales and marketing expenses for fiscal year were  as compared to  in fiscal year  representing an increase of  primarily due to expenses of  associated with the company s newly hired full time oncology sales force and operating expenses for immunomedics europe which increased by  as compared to the same period of general and administrative costs for fiscal year decreased by  as compared to the same period of  primarily due to reduced legal costs as a result of the conclusion of the pharmacia arbitration  which was settled in november net loss for the fiscal year was  or per share  as compared to a net loss of  or per share  in fiscal year the lower net loss of  in as compared to primarily resulted from higher revenues  partially offset by higher operating expenses  as discussed above 
in addition  the net loss per share for fiscal was impacted by the higher weighted average number of shares outstanding during such period as compared to fiscal  which increase was principally due to the conversion of the company s preferred stock see liquidity and capital resources 
fiscal year compared to fiscal year revenues for fiscal year were  as compared to  in fiscal year  representing an increase of  the product sales for fiscal year were  as compared to  in fiscal year  representing an increase of  as the product launch for cea scan and leukoscan did not occur until october and april  respectively 
royalties and license fees for fiscal year increased by  primarily due to the receipt of a nonrecurring  license fee from a corporate partner in fiscal research and development revenue for fiscal year increased by  as compared to fiscal  due to increased grants 
interest and other income for fiscal year decreased by  as compared to fiscal  primarily due to reduced levels of cash available for investments see liquidity and capital resources 
total operating expenses for the fiscal year were  as compared to  in fiscal year  representing an increase of  research and development costs increased by  as compared to fiscal due to expenses associated with the validation of the company s manufacturing facility and expenses related to the filing of the application to the fda for approval of leukoscan 
sales and marketing expenses for fiscal year were  as compared to  in fiscal year  representing an increase of  primarily due to marketing expenses for cea scan of  and operating expenses for immunomedics europe which increased by  as compared to the same period of the general and administrative costs increased by  as compared to fiscal  of which   was principally due to higher legal expenses incurred in connection with the arbitration claim against pharmacia 
net loss for the fiscal year was  or per share  as compared to a net loss of  or per share  in fiscal year the greater net loss resulted principally from higher general and administrative expense partially offset by increased sales and royalty revenues  as explained above 
the net loss per share for the fiscal was impacted by the higher weighted average number of shares outstanding during such period as compared to fiscal  which increase was principally due to the conversion of the company s preferred stock see liquidity and capital resources 
liquidity and capital resources at june   the company had working capital of  representing a decrease of  from june   and had no obligations other than certain lease obligations see note of notes to consolidated financial statements 
the decrease in working capital resulted principally from the funding of operating expenses and capital expenditures 
on june   the company completed an equity financing pursuant to regulation s under the securities act of regulation s  pursuant to which several foreign investors purchased  shares of series d convertible preferred stock the series d preferred for  the terms of the transaction allowed the investors  at their discretion  to convert the series d preferred into shares of the company s common stock during a month period which began in june  at a price equal to of the average market price per share over a day trading period surrounding the date of conversion 
dividends on the series d preferred were payable annually  commencing june   on all shares of series d preferred that have not been converted into common stock as of the dividend payment date 
in august  the company made a dividend payment of  of the series d preferred 
as of june   all  shares of series d preferred had been converted into  shares of the company s common stock 
on december   the company entered into a structured equity line flexible financing agreement the equity line with an investor the investor  pursuant to which  subject to the satisfaction of certain conditions  the company may receive up to an aggregate of million over a month period 
during each three month period each  an investment period  the company  subject to the satisfaction of certain conditions  can require the investor to purchase shares of the company s common stock for an aggregate purchase price of between million and million  and the investor  at its option  may purchase additional shares of common stock for an aggregate purchase price of million 
the company retains the right to provide that no purchases can be made in any given investment period 
the investor may select the dates on which the purchase of shares of the company s common stock will occur 
the purchase price per share to be paid by the investor for the shares of the company s common stock acquired under the equity line will equal of the lowest sales price of the common stock during the three trading days immediately preceding the notice of purchase by the investor 
the investor s obligation to purchase shares of the company s common stock under the equity line is subject to various conditions  including  among other things  the price of the company s common stock being at least such price as the company may from time to time set as the minimum purchase price 
in addition  the investor is not required to purchase  in any investment period  an amount in excess of of the product of the daily average value of open market trading of the common stock and the number of trading days in the investment period during either the current or immediately preceding investment period 
the company granted the investor the right to purchase an additional million during the investment period ended may  as of june   the company received a total of million for which the company issued  shares of common stock 
in connection with entering into the equity line with an investor  the investor received a four year warrant the warrant to purchase  shares of the common stock at an exercise price equal to per share of closing sales price of common stock at the time of issuance 
in addition  the company has agreed to issue to the investor  at the end of each calendar year  an additional four year warrant each  an additional warrant and collectively  the additional warrants to purchase common stock in an amount equal to  shares for each  of common stock purchased by the investor during such year 
the exercise price will be equal to of the weighted average purchase price of the common stock purchased by the investor during the year  provided that the number of shares issuable upon exercise of all the additional warrants will not exceed  in february  the company entered into a master lease agreement  which was subsequently amended  pursuant to which the company may lease equipment for research  development and manufacturing purposes having an aggregate acquisition cost of up to  the basic lease payments under the master lease agreement are determined based on current market rates of interest at the inception of each equipment schedule take down  and are payable in monthly installments over a four year period 
the lease agreement contains an early purchase option  at an amount which is deemed to be fair value 
on november   december   april  and september   the company exercised early purchase options on equipment leased on february   april   june  and august   respectively 
under the lease agreement  continued compliance with certain financial ratios is required and  in the event of default  the company will be required to provide an irrevocable letter of credit which is generally equal to the outstanding balance of lease payments due at the time of default  which was approximately  at june  as of june   the company was not in compliance with certain of these ratios  but the lessor has not yet declared an event of default or requested a letter of credit 
the company does not believe that such a request would have a material adverse effect on the company 
as of june   the company has leased equipment with a cost basis aggregating  under the master lease agreement and recorded lease expense for fiscal years  and of   and  respectively 
the company has a commitment to refinance the outstanding lease obligations and anticipates closing during the second quarter of fiscal year the company s liquid asset position  as measured by its cash  cash equivalents and marketable securities  was  at june   representing a decrease of  from june  it is anticipated that working capital and cash  cash equivalents  and marketable securities will decrease during fiscal year as a result of planned operating expenses and capital expenditures  offset in part by projected revenues from product sales in the u 
s 
and europe 
however  there can be no assurance  as to the amount of revenues  if any  these products will provide 
at present  the company believes that its current cash resources and funds available under the equity line  as discussed above  will be sufficient to fund anticipated operating expenses and capital expenditures through calendar year in addition to the funds available under the equity line  the company believes that it may require additional financial resources by the beginning of calendar year in order for it to continue its projected levels of research and development and clinical trials of its proposed products and regulatory filings for new indications of existing products 
in addition  the company intends to supplement its financial resources from time to time as market conditions permit through additional financing and through collaborative marketing and distribution agreements 
also  the company continues to evaluate various programs to raise additional capital and to seek additional revenues from the licensing of its proprietary technology 
at the present time  the company is unable to determine whether any of these future activities will be successful and  if so  the terms and timing of any definitive agreements 
there can be no assurance that the company will be able to obtain additional funds in the future 
impact of year the company is in the process of conducting a review of its business systems  including its computer systems and manufacturing equipment  and has sent written inquiries to its customers  distributors and vendors as to their progress in identifying and addressing problems that their systems may face in correctly interpreting and processing date information as the year approaches and is reached 
this review is expected to be complete by march based on this review  the company will implement a plan to achieve year compliance 
the company believes that it will achieve year compliance in a manner which will be non disruptive to its operations 
in addition  the company has commenced work on various types of contingency planning to address potential problem areas with internal systems  suppliers and other third parties 
year compliance should not have a material adverse effect on the company  including the company s financial condition  results of operations or cash flow 
the company has incurred no costs to date related to year the company estimates the cost of its year efforts to be approximately  the total cost estimate is based on management s current assessment and is subject to change 
however  the company may encounter problems with supplier and or revenue sources which could adversely affect the company s financial condition  results of operations or cash flow 
the company cannot accurately predict the occurrence and or outcome of any such problems  nor can the dollar amount of such problem be estimated 
in addition  there can be no assurance that the failure to ensure year compliance by a third party would not have a material adverse effect on the company 

